Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Great Point Partners LLC lowered its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 17.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,529,338 shares of the company’s stock after selling 329,397 shares during the period. Vistagen Therapeutics accounts for approximately 1.0% of Great Point Partners LLC’s holdings, making the stock its 27th largest position. Great Point Partners LLC owned about 5.65% of Vistagen Therapeutics worth $5,322,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of VTGN. American Century Companies Inc. boosted its stake in shares of Vistagen Therapeutics by 49.1% during the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock worth $105,000 after acquiring an additional 9,984 shares during the period. Acadian Asset Management LLC bought a new position in Vistagen Therapeutics during the first quarter worth $169,000. AdvisorShares Investments LLC bought a new position in shares of Vistagen Therapeutics in the fourth quarter valued at about $279,000. Blair William & Co. IL lifted its stake in shares of Vistagen Therapeutics by 29.2% during the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after buying an additional 20,000 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Vistagen Therapeutics during the 4th quarter worth about $1,262,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

Vistagen Therapeutics Price Performance

VTGN stock opened at $3.03 on Tuesday. The business’s fifty day moving average price is $3.42 and its two-hundred day moving average price is $3.94. The stock has a market capitalization of $81.89 million, a price-to-earnings ratio of -1.46 and a beta of 0.80. Vistagen Therapeutics, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $5.86.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06. Vistagen Therapeutics had a negative net margin of 3,421.85% and a negative return on equity of 35.12%. The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the previous year, the company earned ($0.94) EPS. Research analysts expect that Vistagen Therapeutics, Inc. will post -1.79 EPS for the current year.

Analyst Ratings Changes

Separately, William Blair raised shares of Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.